ALIGN TECHNOLOGY INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ALIGN TECHNOLOGY INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $387.13M | Feb 24, 2011 |
| FY2010 | Dec 31, 2009 | $312.33M | Feb 24, 2011 |
| FY2010 | Dec 31, 2008 | $303.98M | Feb 24, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.03B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.00B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $3.86B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.73B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.95B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $2.47B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $2.41B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.97B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.47B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $1.08B | Feb 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.47B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.08B | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $845.49M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $761.65M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $660.21M | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $560.04M | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $479.74M | Feb 28, 2014 |
| FY2012 | Dec 31, 2010 | $387.13M | Mar 1, 2013 |
| FY2011 | Dec 31, 2009 | $312.33M | Feb 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.71B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.80B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.71B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.63B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.94B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.76B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.74B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.45B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.12B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $815.29M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $410.35M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $421.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $445.05M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $361.57M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $772.02M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.78B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $442.78M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $400.24M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $231.42M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $189.68M | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $545.76M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $607.63M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $643.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $642.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $976.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $387.17M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $542.49M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $466.56M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $353.61M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $248.92M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $369.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $364.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $346.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $305.26M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $250.32M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $175.31M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $157.36M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $128.90M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $97.56M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $75.72M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.76B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.70B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.67B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.71B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.20B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.07B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $852.40M | Feb 26, 2021 |
| FY2015 | Dec 31, 2015 | $390.24M | Feb 25, 2016 |
| FY2015 | Dec 31, 2014 | $332.07M | Feb 25, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $593.22M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $738.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $785.78M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $568.73M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.17B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $662.17M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $747.27M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $554.68M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $438.54M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $247.65M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $115.58M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $177.72M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $291.90M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $401.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $154.92M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $24.40M | Feb 28, 2020 |
| FY2019 | Jan 15, 2019 | $27.00M | Feb 28, 2020 |
| FY2020 | Dec 31, 2018 | $223.31M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $195.70M | Feb 28, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.23B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.21B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $6.08B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.95B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.94B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $4.83B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.50B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.05B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.78B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.40B | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.18B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.36B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.45B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.35B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.32B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.60B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.15B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $799.57M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $629.72M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $400.76M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.05B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.85B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $3.63B | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $3.60B | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $3.62B | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $3.23B | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $1.35B | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $1.25B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $1.15B | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $999.31M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $442.63M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $419.53M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $407.55M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $418.55M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $444.82M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $63.92M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $64.03M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $64.61M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $61.04M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.46B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.48B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.45B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.57B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.62B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $2.22B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $439.91M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $378.14M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $267.27M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $131.45M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $937.44M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $942.05M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.10B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $960.84M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $550.43M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $636.90M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $449.51M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $389.28M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 22 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 5 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 22 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 28, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 71.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 73.85M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 75.08M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 77.27M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 78.71M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 78.86M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 78.43M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 79.78M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 80.04M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 79.55M | Feb 28, 2018 |